

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

'Applicant:

Jim Wells et al.

Docket No.:

39750-0002DV1

Serial No.:

10/082,046

Group Art Unit:

1639

Filing Date:

02/20/2002

Examiner:

Epperson, Jon D

For:

METHODS FOR RAPIDLY IDENTIFYING SMALL ORGANIC

MOLECULE LIGANDS FOR BINDING TO BIOLOGICAL

TARGET MOLECULES

TERMINAL DISCLAIMER UNDER 37 CFR § 1.321(c)

Commissioner for Patents Washington, D.C. 20231

Dear Sir:

The owner, Sunesis Pharmaceuticals, Inc., having a principal place of business at 1. 341 Oyster Point Boulevard, South San Francisco, California 94080, represents that it is the owner of the entire right, title and interest in the invention disclosed and claimed in the aboveidentified patent application, and is also the owner of the entire right, title and interest in the invention disclosed in U.S. Patent No. 6,335,155.

Sunesis Pharmaceuticals, Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer, of prior U.S. Patent No. 6,335,155. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application, and is binding upon the grantee, its successors or assigns.

CERTIFICATE OF MAILING (37 CFR 1.10(a))

CERTIFICATE OF MAILING BY "EXPRESS MAIL" - Rule 10: I hereby certify that this correspondence is being deposited on April 18, 2003 with the U.S. Postal Service "Express Mail Post Office to Addressee" under 37 CFR 1.10 as Express Mail No. EV165101142US addressed to: Box Fee Amendment, Commissioner for Patents, Washington, D.C. 20231

Date: April 18, 2003

04/22/2003 ADSMAN1 00000088 081641

10082046

In making the above disclaimer, the owner does not disclaim the terminal part of any

patent granted on the instant application that would extend to the expiration date of the full

statutory term as defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any

terminal disclaimer. In the event that it later is found invalid by a court of competent

jurisdiction, is statutorily disclaimed in whole, or terminally disclaimed under 37 C.F.R. 1.321;

has all claims canceled by a re-examination certificate; is reissued; or is in any manner

terminated prior to the expiration of its full statutory term as presently shortened by any terminal

disclaimer.

2. For submission on behalf of an organization (e.g., corporation, partnership,

university, government agency, etc.), the undersigned is empowered to act on behalf of the

organization.

3. I hereby declare that all statements made herein of my own knowledge are true,

that all statements made on information and belief are believed to be true, and further that these

statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code, and that such willful false statement may jeopardize the validity of the application or any

patent issued thereon.

4. The undersigned is an attorney of record.

5. The Commissioner is authorized to charge any fees, including any fees for

extension of time, or credit overpayment to Deposit Account No. 08-1641 (Attorney Docket No.:

39750-0002DV1C2). A duplicate copy of the transmittal letter accompanying the present

Terminal Disclaimer is enclosed.

Respectfully submitted,

Date: April 18, 2003

Reg. No. 33,055

HELLER EHRMAN WHITE & McAULIFFE LLP

Customer No. 25213

275 Middlefield Road

Menlo Park, California 94025

Telephone: (650) 324-7000

Facsimile: (650) 324-0638

2